Teriflunomide Attenuates Immunopathological Changes in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark...

Descripción completa

Detalles Bibliográficos
Autores principales: Ringheim, Garth E., Lee, Lan, Laws-Ricker, Lynn, Delohery, Tomas, Liu, Li, Zhang, Donghui, Colletti, Nicholas, Soos, Timothy J., Schroeder, Kendra, Fanelli, Barbara, Tian, Nian, Arendt, Christopher W., Iglesias-Bregna, Deborah, Petty, Margaret, Ji, Zhongqi, Qian, George, Gaur, Rajula, Weinstock, Daniel, Cavallo, Jean, Telsinskas, Juventas, McMonagle-Strucko, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2013
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812666/
https://www.ncbi.nlm.nih.gov/pubmed/24198809
http://dx.doi.org/10.3389/fneur.2013.00169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812666/
https://www.ncbi.nlm.nih.gov/pubmed/24198809
http://dx.doi.org/10.3389/fneur.2013.00169

Ejemplares similares